In the clinical practice, givosiran, an RNAi therapeutic drug by targeting aminolevulinic acid synthase 1 (ALAS1) has been developed for the treatment of acute hepatic porphyria (AHP) [47]. This evidence concerns the gene ALAS1 and anhaptoglobinemia.